Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. HC Wainwright raised their price objective on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 12th. D Boral Capital downgraded shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics presently has a consensus rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Price Performance

Shares of NASDAQ:ENLV opened at $0.94 on Friday. The stock has a market cap of $223.14 million, a price-to-earnings ratio of -1.71 and a beta of 1.52. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10. The stock’s 50 day moving average price is $0.91 and its 200 day moving average price is $1.07.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ENLV. Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics in the third quarter worth approximately $57,000. Jane Street Group LLC boosted its stake in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Finally, Citizens Financial Group Inc. RI purchased a new position in Enlivex Therapeutics during the 3rd quarter worth approximately $241,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.